Works matching DE "GRAFT versus host reaction"


Results: 838
    1
    2
    3
    4

    Tocilizumab in transplantation.

    Published in:
    European Journal of Clinical Pharmacology, 2020, v. 76, n. 6, p. 765, doi. 10.1007/s00228-020-02864-6
    By:
    • Mosharmovahed, Banafsheh;
    • Fatahi, Yousef;
    • Mohebbi, Bahareh;
    • Ghorbanian, Sohrab Ali;
    • Assadiasl, Sara
    Publication type:
    Article
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14
    15
    16
    17
    18
    19

    Association of British Clinical Diabetologists and Renal Association guidelines on the detection and management of diabetes post solid organ transplantation.

    Published in:
    Diabetic Medicine, 2021, v. 38, n. 6, p. 1, doi. 10.1111/dme.14523
    By:
    • Chowdhury, Tahseen A.;
    • Wahba, Mona;
    • Mallik, Ritwika;
    • Peracha, Javeria;
    • Patel, Dipesh;
    • De, Parijat;
    • Fogarty, Damian;
    • Frankel, Andrew;
    • Karalliedde, Janaka;
    • Mark, Patrick B.;
    • Montero, Rosa M.;
    • Pokrajac, Ana;
    • Zac‐Varghese, Sagen;
    • Bain, Stephen C.;
    • Dasgupta, Indranil;
    • Banerjee, Debasish;
    • Winocour, Peter;
    • Sharif, Adnan
    Publication type:
    Article
    20
    21
    22
    23
    24
    25
    27
    28
    29
    30
    31
    32
    33

    Pre-transplantation risk factors to develop sclerotic chronic GvHD after allogeneic HSCT: A multicenter retrospective study from the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC).

    Published in:
    Bone Marrow Transplantation, 2015, v. 50, n. 2, p. 253, doi. 10.1038/bmt.2014.244
    By:
    • Detrait, M Y;
    • Morisset, S;
    • Peffault de Latour, R;
    • Yakoub-Agha, I;
    • Crocchiolo, R;
    • Tabrizi, R;
    • Bay, J-O;
    • Chevalier, P;
    • Barraco, F;
    • Raus, N;
    • Vigouroux, S;
    • Magro, L;
    • Mohty, M;
    • Milpied, N;
    • Blaise, D;
    • Socié, G;
    • Michallet, M
    Publication type:
    Article
    34
    35

    Malnutrition in patients with chronic GVHD.

    Published in:
    Bone Marrow Transplantation, 2014, v. 49, n. 10, p. 1300, doi. 10.1038/bmt.2014.145
    By:
    • Bassim, C W;
    • Fassil, H;
    • Dobbin, M;
    • Steinberg, S M;
    • Baird, K;
    • Cole, K;
    • Joe, G;
    • Comis, L E;
    • Mitchell, S A;
    • Grkovic, L;
    • Edwards, D;
    • Mays, J W;
    • Cowen, E W;
    • Pulanic, D;
    • Williams, K M;
    • Gress, R E;
    • Pavletic, S Z
    Publication type:
    Article
    36
    37

    TLI in refractory chronic GVHD.

    Published in:
    Bone Marrow Transplantation, 2013, v. 48, n. 6, p. 854, doi. 10.1038/bmt.2012.240
    By:
    • Devillier, R;
    • Castagna, L;
    • Gonzague, L;
    • El-Cheikh, J;
    • Fürst, S;
    • Faucher, C;
    • Michel, R;
    • Blaise, D
    Publication type:
    Article
    38
    39
    40
    41
    42
    43

    Biomarkers of immune activation to screen for severe, acute GVHD.

    Published in:
    Bone Marrow Transplantation, 2011, v. 46, n. 4, p. 601, doi. 10.1038/bmt.2010.165
    By:
    • August, K. J.;
    • Chiang, K.-Y.;
    • Bostick, R. M.;
    • Flanders, W. D.;
    • Waller, E. K.;
    • Langston, A.;
    • Worthington-White, D.;
    • Rowland, P.;
    • Moore, K. F.;
    • Khoury, H. J.;
    • Horan, J. T.
    Publication type:
    Article
    44
    45
    46
    47
    48

    CD34<sup>+</sup> cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignancies.

    Published in:
    Bone Marrow Transplantation, 2010, v. 45, n. 12, p. 1699, doi. 10.1038/bmt.2010.49
    By:
    • Holtan, S. G.;
    • Hogan, W. J.;
    • Elliott, M. A.;
    • Ansell, S. M.;
    • Inwards, D. J.;
    • Porrata, L. F.;
    • Johnston, P. B.;
    • Micallef, I. N.;
    • Lacy, M. Q.;
    • Gastineau, D. A.;
    • Litzow, M. R.
    Publication type:
    Article
    49
    50